Circulating Ghrelin in Patients with Gastric or Colorectal Cancer

Qi Huang; Yue-Zu Fan; Bu-Jun Ge; Qin Zhu; Zhi-Yuan Tu
March 2007
Digestive Diseases & Sciences;Mar2007, Vol. 52 Issue 3, p803
Academic Journal
Abstract??The purpose of this study was to investigate the pathophysiologic change of ghrelin in gastric and colorectal cancer patients, especially in those with cachexia. Fifty-eight gastric cancer patients, 20 colorectal cancer patients, and 24 healthy control individuals were included in this study. Thirty-one patients were defined as cachectic, based on the percentage of weight loss versus the previous normal weight. The remaining 47 patients were defined as noncachectic. Peripheral hormones, including ghrelin, insulin, leptin, growth hormone, glucagon, and cortisol, and body composition parameters were measured. Plasma ghrelin levels did not increase significantly in cachectic gastric (p=0.352) or colorectal (p=0.871) cancer patients as compared with controls and were not correlated with nutrition status and other hormones. The location of gastric cancer (proximal vs. distal) had no influence on ghrelin levels (p=0.966). These findings suggest that gastric and colorectal cancers may have their special effects on the production of ghrelin. Gastric or colorectal cancer cachexia may be partly due to the lack of increase in ghrelin, which makes exogenous ghrelin therapy feasible in this setting.


Related Articles

  • Continuing Medical Education Questions: July 2011. DeVault, Kenneth R.; Carey, Emily; Hanouneh, Ibrahim; Kane, Saul; Navaneethan, Udayakumar // American Journal of Gastroenterology;Jul2011, Vol. 106 Issue 7, p1207 

    A quiz concerning colonoscopy of elderly patients with colorectal cancer is presented.

  • The Prognostic Significance of Chromosome Abnormalities in Colon Tumors. Lubs, Herbert A.; Kotler, Stuart // Annals of Internal Medicine;Aug67, Vol. 67 Issue 2, p328 

    Provides information on a study that examined the clinical-cytogenetic correlations in patients with colon tumors. Methodology of the study; Results and discussion on the study.

  • Influence of stage at diagnosis on survival differences for rectal cancer in three European populations. Monnet, E; Faivre, J; Raymond, L; Garau, I // British Journal of Cancer;10/1/99, Vol. 81 Issue 3, p463 

    Important differences have recently been highlighted between European countries in the survival of colorectal cancer patients. As data on stage at diagnosis were available for rectal cancers in three European population-based registries (Geneva Switzerland; Côte d'Or, France; Mallorca,...

  • A cohort study of dietary iron and heme iron intake and risk of colorectal cancer in women. Kabat, G. C.; Miller, A. B.; Jain, M.; Rohan, T. E. // British Journal of Cancer;12/3/2007, Vol. 97 Issue 11, p1600 

    A correction to the article "A cohort study of dietary iron and heme iron intake and risk of colorectal cancer in women" that was published in the previous issue is presented.

  • Letter to the Editor: Worse prognosis caused by anti-EGFR treatment in advanced colorectal cancer patients with KRAS mutation. Yin, Peihao; Qiu, Yanyan; Li, Qi // International Journal of Colorectal Disease;May2013, Vol. 28 Issue 5, p733 

    A letter to the editor is presented in response to the article "Worse prognosis caused by anti-EGFR treatment in advanced colorectal cancer patients with KRAS mutation," by Peihao Yin, Yanyan Qiu and Qi Li, published in the previous issue of the periodical.

  • QuickStats.  // MMWR: Morbidity & Mortality Weekly Report;3/27/2015, Vol. 64 Issue 11, p310 

    A chart is presented that shows the mortality rates of U.S. people with colorectal cancer from 1999 to 2013.

  • Ziv-aflibercept yields encouraging results in metastatic colorectal cancer.  // Hem/Onc Today;11/10/2012, Vol. 13 Issue 21, p26 

    The article reports on a study by Doctor Eric Van Cutsem, head of digestive oncology and professor of medicine at University Hospital Gasthuisberg in Leuven, Belgium, stating that the addition of ziv-aflibercept to infusional FOLFIRI improved survival in metastatic colorectal cancer patients.

  • Adverse Reaction Research.  // Reactions Weekly;3/13/2010, Issue 1292, p3 

    The article focuses on a study which examined the use of homozygous UGT1A1*28 genotype to predict grade 3 4 treatment-induced neutropenia in colorectal cancer patients receiving irinotecan.

  • The outcome of young colorectal cancer patients is controversial. Fu, Jian-Fei // Techniques in Coloproctology;Dec2013, Vol. 17 Issue 6, p671 

    A letter to the editor is presented in response to an article about patients with colorectal cancer.


Read the Article


Sign out of this library

Other Topics